Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$59.69 USD
+1.19 (2.03%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $59.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 241 - 260 ( 311 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Excitement Building for April Data; We''re In; Re-Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Tirasemtiv Phase IIb Trial Design Finalized, Study to Initiate in 4Q12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Tirasemtiv Phase IIb Trial Design Finalized, Study to Initiate in 4Q12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv mecarbil: a promising new drug in systolic heart failure
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv mecarbil: a promising new drug in systolic heart failure
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Raises $60MM to Fully Fund Phase IIb Study - Updating our Models
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Raises $60MM to Fully Fund Phase IIb Study - Updating our Models
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Another Step Forward: Omecamtiv Progresses to Second Cohort of ATOMIC
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Another Step Forward: Omecamtiv Progresses to Second Cohort of ATOMIC
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M